0001104659-21-076497.txt : 20210603 0001104659-21-076497.hdr.sgml : 20210603 20210603175616 ACCESSION NUMBER: 0001104659-21-076497 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210601 FILED AS OF DATE: 20210603 DATE AS OF CHANGE: 20210603 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Bitterman Kevin CENTRAL INDEX KEY: 0001591747 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38944 FILM NUMBER: 21993901 MAIL ADDRESS: STREET 1: C/O POLARIS VENTURE PARTNERS STREET 2: 1000 WINTER STREET, SUITE 3350 CITY: WALTHAM STATE: MA ZIP: 02451 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Akero Therapeutics, Inc. CENTRAL INDEX KEY: 0001744659 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 601 GATEWAY BOULEVARD, SUITE 350 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 650-487-6488 MAIL ADDRESS: STREET 1: 601 GATEWAY BOULEVARD, SUITE 350 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 4 1 tm2118278d3_4seq1.xml OWNERSHIP DOCUMENT X0306 4 2021-06-01 0 0001744659 Akero Therapeutics, Inc. AKRO 0001591747 Bitterman Kevin C/O AKERO THERAPEUTICS, INC. 601 GATEWAY BLVD, SUITE 350 SOUTH SAN FRANCISCO, CA 94080 1 0 0 0 Stock Option (Right to Buy) 26.32 2021-06-01 4 A 0 13000 0 A 2031-05-31 Common Stock 13000 13000 D This option shall vest in full upon the earlier of (i) June 1, 2022 or (ii) the date of the next annual meeting, all vesting shall cease if the director resigns from the Board or otherwise ceases to service as a director. /s/ Jonathan Young, attorney-in-fact 2021-06-03